Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04150965
Title Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Multiple Myeloma Research Consortium
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.